Iridex Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2025
MWN-AI** Summary
Iridex Corporation (Nasdaq: IRIX), a leader in laser-based medical systems, has released its preliminary operational and financial results for the fourth quarter and full year ending January 3, 2026. The company anticipates fourth-quarter revenues between $14.6 million and $14.8 million, a significant increase from $12.7 million in the previous year, translating to year-over-year growth of approximately 15% to 17%. In this quarter, Iridex achieved positive cash flow and sold 15,800 Cyclo G6® probes, marking an increase from 13,300 units sold in the same quarter of 2024. However, sales of Cyclo G6 Glaucoma Laser Systems slightly declined, with 44 units sold compared to 47 in the prior year.
For the full year 2025, projected revenues range from $52.5 million to $52.7 million, up from $48.7 million in 2024, indicating an 8% growth. The company expects to report positive adjusted EBITDA for the year, having sold 57,700 Cyclo G6® probes and 133 Cyclo G6® Glaucoma Laser Systems, both representing increases over the previous year’s figures.
CEO Patrick Mercer highlighted the company’s focused cost reductions, improved gross margins, and enhanced commercial efficiency as key contributors to their success. These efforts resulted in a fifth consecutive quarter of revenue growth and a reduction in operating expenses. The preliminary results, while promising, are subject to further review and are yet to be finalized through external auditing.
Overall, Iridex's solid performance underscores its strategic initiatives aimed at strengthening its financial position and expanding its market reach in the ophthalmology sector. The firm’s proprietary MicroPulse® technology continues to play a crucial role in its product offerings for treating glaucoma and retinal diseases.
MWN-AI** Analysis
Iridex Corporation's recent preliminary operational and financial results for Q4 and full year 2025 reflect a promising trajectory for the company. With total revenue expected to be between $14.6 million and $14.8 million for Q4, marking a 15% to 17% increase year-over-year, and an annual revenue range of $52.5 million to $52.7 million—an 8% increase—it is clear that Iridex is on a growth path. These numbers indicate a solid demand for their industry-leading products, particularly the Cyclo G6® probes, where sales have reached 57,700 units in 2025 from 55,400 in the previous year.
Positive cash flow achievement in Q4 and expected adjusted EBITDA for the full year are significant highlights that not only enhance Iridex's financial health but also bolster investor confidence. The company's ongoing focus on operational efficiencies, cost reductions, and gross margin improvements seems to be yielding results, as evidenced by these metrics.
However, potential investors should remain cautious as these results are preliminary and subject to adjustments pending year-end financial review and external audit. The forward-looking statements about continued revenue growth and operational efficiencies, while promising, come with inherent risks that could affect outcomes.
From a market perspective, those considering investment in Iridex Corporation might view the current trajectory as optimistic but should stay informed about potential risks as outlined in the company's filings with the SEC. The company's strategic positioning in the ophthalmology sector amid growing global healthcare demands offers future potential. Considering this, long-term investors may find Iridex an attractive candidate for portfolio diversification, particularly for those interested in the healthcare technology sector. An astute approach would be to monitor the company's year-end financial results and assess its performance against industry benchmarks before making decisive investment choices.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
MOUNTAIN VIEW, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced preliminary unaudited operational and financial results for the fourth quarter and full year ended January 3, 2026.
Fourth Quarter 2025 Results
- Total revenue is expected to be between $14.6 million and $14.8 million compared to $12.7 million in the prior year quarter, representing year-over-year growth between 15% and 17%
- Achieved positive cash flow in the fourth quarter
- Sold 15,800 Cyclo G6® probes compared to 13,300 in the prior year quarter
- Sold 44 Cyclo G6 Glaucoma Laser Systems, compared to 47 in the prior year quarter
Full Year 2025 Results
- Total revenue is expected to be between $52.5 million and $52.7 million compared to $48.7 million in 2024, representing year-over-year growth of 8%
- The company expects to achieve positive adjusted EBITDA in 2025
- Sold 57,700 Cyclo G6® probes, compared to 55,400 in the prior year
- Sold 133 Cyclo G6® Glaucoma Laser Systems compared to 125 in the prior year
“In 2025, we strengthened our financial position through focused cost reductions, gross margin expansion, and improved commercial efficiency, and increased probe sales,” said Patrick Mercer, President and CEO of IRIDEX. “When we set and communicated our goals for 2025, we were clear about what we intended to accomplish—and in 2025 we delivered. The actions we took drove a fifth consecutive quarter of year-over-year revenue growth, reduced operating expenses, and improved adjusted EBITDA. We achieved positive cash flow in the fourth quarter of 2025, and we expect to achieve positive adjusted EBITDA for the full year 2025.”
These preliminary results are based on management's initial analysis of operations for the quarter and year ended January 3, 2026, and are subject to the completion of the Company’s year-end financial reporting processes, further internal review, potential adjustments, and audit by the Company's external auditors.
About Iridex Corporation
Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated laser treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the Iridex website at www.iridex.com.
MicroPulse® is a registered trademark of Iridex Corporation, Inc. in the United States, Europe and other jurisdictions. © 2025 Iridex Corporation. All rights reserved.
Safe Harbor Statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, including those statements concerning continued revenue growth, operational efficiencies, positive cash flow, and financial and operating results. These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors. Please see a detailed description of these and other risks further described in the “Risk Factors” section of Iridex’s most recent Annual Report on Form 10-K, as well as in Iridex’s other reports filed with or furnished to the United States Securities and Exchange Commission (“SEC”), available at www.sec.gov. Forward-looking statements contained in this announcement are made as of this date and will not be updated.
Investor Relations Contact
Philip Taylor
Gilmartin Group
investors@iridex.com
FAQ**
How does IRIDEX Corporation IRIX plan to maintain its positive cash flow trend and what specific strategies will be implemented to sustain revenue growth in the coming quarters?
Can you provide more details on the factors contributing to the observed 15%-17% revenue growth in the fourth quarter of 20for IRIDEX Corporation IRIX, and how this compares to industry trends?
What steps is IRIDEX Corporation IRIX taking to improve its commercial efficiency and gross margin, and how will these efforts impact future product launches or developments?
With the increase in sales of Cyclo G6® probes, how does IRIDEX Corporation IRIX plan to address potential market challenges and competition in the ophthalmology sector moving forward?
**MWN-AI FAQ is based on asking OpenAI questions about IRIDEX Corporation (NASDAQ: IRIX).
NASDAQ: IRIX
IRIX Trading
-0.77% G/L:
$1.3395 Last:
2,580 Volume:
$1.35 Open:
